ELV insider transactions (Form 4) Open-market purchases and sales. 52 grants, option exercises and tax withholdings are not shown.
Filed
Insider Type
Shares
Price
Value
Since
Score
Nov 20 New SEC
Ramiro G. Peru ✦ Spy Director Buy
1,00011,908 held (+9%)
$383.86
$384K
—
—
Nov 6 SEC
Ratnakar Lavu ✦ Spy Evp & Chief Digital Info Ofr Sell
1,30014,849 held (−8%)
$440.00
$572K
-11.1%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
2,34322,099 held (−10%)
$441.34
$1.0M
-11.4%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
1,72024,442 held (−7%)
$440.44
$758K
-11.2%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
1,66028,122 held (−6%)
$436.20
$724K
-10.3%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
1,16026,162 held (−4%)
$439.25
$510K
-11.0%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
82720,192 held (−4%)
$446.05
$369K
-12.3%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
56027,562 held (−2%)
$437.07
$245K
-10.5%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
48021,619 held (−2%)
$442.61
$212K
-11.6%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
44021,179 held (−2%)
$443.81
$195K
-11.9%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
40030,103 held (−1%)
$434.00
$174K
-9.9%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
32129,782 held (−1%)
$435.25
$140K
-10.1%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
27319,919 held (−1%)
$447.19
$122K
-12.5%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
24027,322 held (−1%)
$438.22
$105K
-10.7%
—
Oct 23 SEC
Mark Kaye ✦ Spy CFO Sell
16021,019 held (−1%)
$444.85
$71K
-12.1%
—
Jul 17 SEC
Gail Boudreaux ✦ Spy CEO, President Buy
2,045171,976 held (+1%)
$368.25
$753K
+6.2%
—
Jul 17 SEC
Ramiro G. Peru ✦ Spy Director First buy Buy
1,00010,908 held (+10%)
$366.05
$366K
+6.9%
—
Jul 17 SEC
Gail Boudreaux ✦ Spy CEO, President Buy
680169,931 held (+0%)
$366.41
$249K
+6.7%
—
Jun 15 SEC
Ronald W. Penczek ✦ Spy Cao & Controller Sell
3693,740 held (−9%)
$403.16
$149K
-3.0%
—
Jun 12 SEC
Robert L. Dixon Jr. ✦ Spy Director Sell
15110,734 held (−1%)
$401.77
$61K
-2.6%
—
May 20 SEC
Ronald W. Penczek ✦ Spy Cao & Controller Sell
1,5314,109 held (−27%)
$403.13
$617K
-3.0%
—
Mar 23 SEC
Amy W. Schulman ✦ Spy Director Sell
26218 held (−11%)
$287.50
$7K
+36.0%
—
Mar 9 SEC
Charles Morgan Kendrick Jr. ✦ Spy President Sell
3,19611,791 held (−21%)
$284.92
$911K
+37.3%
—
Mar 6 SEC
Steven H. Collis ✦ Spy Director First buy Stake +469% Buy
3,0003,639 held (+469%)
$289.84
$870K
+34.9%
54
Play with ELV in the Research Lab
Pre-set to ELV's latest insider buy of $10K or more (Nov 20, 2026: Ramiro G. Peru, $384K). Tap to change anything.
All tools →
Quick backtest: did buys like this beat the market?
Insiders buying Any 1 2 3+
CEO or CFO Any Yes No
Dollar size Any < $250K $250K–1M $1M+
Stock before Any Down 20%+ Down 0–20% Up
Tap a setting to see how 6,290 past insider buys did.
Open the full Backtester →
Research Lab Chart By quarter Setup Odds After the buys Transactions Insiders Earnings Short selling Congress FAQ
Share price and insider trades
ELV close Insider buy Insider sale
250 300 350 400 450 Dec Jan 2026 Feb Mar Apr May Jun Jul Aug Sep Oct Nov E Earnings release filed 2026-01-28 E Earnings release filed 2026-04-22 E Earnings release filed 2026-07-15 E Earnings release filed 2026-10-21 Sold $7,475 on 2026-03-12 · Amy W. Schulman Sold $60,667 on 2026-06-11 · Robert L. Dixon Jr. Sold $148,766 on 2026-06-12 · Ronald W. Penczek Bought $383,860 on 2026-11-19 · Ramiro G. Peru Sold $572,000 on 2026-11-05 · Ratnakar Lavu Sold $617,192 on 2026-05-19 · Ronald W. Penczek Bought $869,520 on 2026-03-05 · Steven H. Collis Sold $910,604 on 2026-03-06 · Charles Morgan Kendrick Jr. Bought $1,368,280 on 2026-07-17 · Gail Boudreaux, Ramiro G. Peru Sold $4,658,357 on 2026-10-22 · Mark Kaye
Bought, 12 months $2.6M
Sold, 12 months $7.0M
Insiders buying 3
Insiders selling 6
Elevance Health insider trading at a glance (Nov 20, 2026): in the past 12 months, 3 insiders bought $2.6M and 6 sold $7.0M of ELV stock on the open market; P/E 14.9 vs. a sector median of 25.0.
Setup Odds: how past setups like this did ELV's latest insider buying (Nov 20, 2026) matched against every similar buy since 2020.
How it works →
1 insider buying no CEO or CFO $250K–$1M stock down 0–20% in 3 months
111 of 221 past setups like this beat the S&P 500 over the next 90 days (50%) , against 46% for all insider buys.
Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500 Did not beat the S&P 500
50 of 100 similar setups beat the S&P 500 beat didn't
−40% −20% 0% = S&P +20% +40%
How those 221 cases did vs. the S&P 500 over 90 days. Hover a bar for counts.
Outcome Cloud each dot is one of these 221 past setups; the white ring is ELV's buy, result due in 90 days
Beat the S&P 500 ↑ Lagged ↓ -50% -25% +0% +25% +50% 2020 2021 2022 2023 2024 2025 2026 BDC 2022-06-21: +31% vs S&P +4% BHVN 2026-03-09: +6% vs S&P +9% ASPN 2023-09-07: +84% vs S&P +3% ADSK 2025-03-24: +10% vs S&P +4% BSM 2026-05-14: +7% vs S&P +4% ASMB 2024-01-19: +29% vs S&P +4% ADP 2026-05-11: +29% vs S&P +5% COLD 2020-12-10: +3% vs S&P +7% OPBK 2022-12-15: -19% vs S&P +0% WY 2022-06-09: -10% vs S&P -0% ACRE 2022-02-25: +5% vs S&P -7% CROX 2024-10-30: -5% vs S&P +5% BMRN 2022-11-02: +37% vs S&P +9% ARKR 2022-12-22: +9% vs S&P +3% ACGL 2026-05-04: +7% vs S&P +4% BRK-B 2026-05-06: +10% vs S&P +5% CODI 2020-06-04: +5% vs S&P +15% CLAR 2024-11-14: +11% vs S&P +2% MBC 2024-08-13: +17% vs S&P +11% BXP 2020-03-12: -10% vs S&P +29% BBW 2022-03-21: +1% vs S&P -17% BXP 2023-03-15: +2% vs S&P +13% TREIX 2023-01-05: +2% vs S&P +8% ADBE 2022-01-10: -15% vs S&P -4% ALLE 2025-11-25: -4% vs S&P +1% COLB 2021-11-29: +13% vs S&P -5% AASP 2026-04-29: +40% vs S&P +4% CE 2022-02-28: +15% vs S&P -5% CME 2024-01-19: +4% vs S&P +4% CME 2020-06-12: -6% vs S&P +10% MBUU 2024-02-23: -16% vs S&P +4% AUR 2025-08-07: -28% vs S&P +7% BX 2022-04-28: -9% vs S&P -6% CDW 2023-05-04: +21% vs S&P +12% BANF 2021-09-14: +23% vs S&P +5% CAI 2026-07-13: +74% vs S&P +4% AFG 2025-02-24: +3% vs S&P -3% CLMT 2023-11-21: +10% vs S&P +11% ATRA 2021-06-15: +15% vs S&P +6% OPBK 2022-08-31: -3% vs S&P +0% AJG 2025-11-03: +3% vs S&P +2% BRO 2023-03-17: +23% vs S&P +13% ALLE 2026-03-12: -11% vs S&P +9% ONEW 2026-02-13: -6% vs S&P +10% BUR 2025-03-10: +4% vs S&P +7% ALKS 2022-11-16: +24% vs S&P +5% CBSH 2022-06-13: +9% vs S&P +9% BHM 2023-03-14: -16% vs S&P +11% CLFD 2025-12-15: -2% vs S&P -2% AGCO 2025-05-07: +21% vs S&P +12% BETA 2026-05-21: +65% vs S&P +4% CDZI 2026-05-28: -8% vs S&P +2% CFR 2022-05-04: -5% vs S&P -4% AESI 2024-10-28: +21% vs S&P +5% OPBK 2022-03-08: -6% vs S&P -1% BPRN 2024-03-18: +3% vs S&P +6% CAG 2021-01-11: +10% vs S&P +9% AMD 2025-02-12: +1% vs S&P -2% COST 2022-06-08: +11% vs S&P -5% DAL 2024-07-15: +20% vs S&P +4% BSTZ 2021-03-23: +18% vs S&P +8% ALTO 2021-05-20: -18% vs S&P +6% AUB 2024-06-10: +22% vs S&P +1% TBLD 2022-01-05: -7% vs S&P -3% CLX 2025-11-24: +18% vs S&P +3% CMG 2021-04-27: +23% vs S&P +6% CRC 2021-12-22: +8% vs S&P -4% ALSN 2025-08-25: -4% vs S&P +3% AMG 2023-03-17: +13% vs S&P +13% C 2020-10-16: +62% vs S&P +9% RBB 2024-03-18: +2% vs S&P +6% AXP 2025-03-11: +18% vs S&P +8% MRNA 2020-02-18: +323% vs S&P -12% CCOI 2022-11-15: +19% vs S&P +4% CVS 2020-05-13: +8% vs S&P +19% AAP 2023-09-14: +3% vs S&P +5% AMSF 2021-08-26: +7% vs S&P +6% BA 2026-05-22: -2% vs S&P +3% CRM 2025-09-10: +8% vs S&P +5% CNNE 2020-03-13: +16% vs S&P +12% AAON 2025-12-15: +9% vs S&P -2% CODI 2022-05-16: +9% vs S&P +7% BSM 2024-08-15: +7% vs S&P +8% BAC 2023-11-03: +19% vs S&P +13% WWD 2021-08-04: +6% vs S&P +6% BTT 2022-01-25: -9% vs S&P -1% CMCL 2026-08-17: -10% vs S&P -2% CKX 2022-09-06: -3% vs S&P +3% AUNA 2026-06-01: +14% vs S&P +2% BPRN 2025-02-12: +6% vs S&P -2% AMH 2022-11-23: +3% vs S&P -0% AUBN 2020-03-12: +34% vs S&P +29% ARCC 2023-05-04: +13% vs S&P +12% GBLI 2021-11-16: +0% vs S&P -6% CRMD 2025-10-27: -34% vs S&P +1% COP 2025-06-17: -3% vs S&P +11% CBSH 2022-07-28: -0% vs S&P -6% AMT 2026-03-12: +8% vs S&P +9% RBB 2022-05-02: +6% vs S&P -0% BKGM 2020-03-09: -10% vs S&P +17% AESI 2025-02-28: -35% vs S&P -0% BWB 2020-09-03: +21% vs S&P +7% BRK-A 2022-07-07: +0% vs S&P -3% ASMB 2024-11-26: -17% vs S&P -0% ARDX 2025-02-26: -22% vs S&P -0% ATR 2022-11-03: +24% vs S&P +11% BG 2026-08-04: -11% vs S&P -2% AN 2022-05-23: +17% vs S&P +7% CHD 2021-03-04: +10% vs S&P +12% BL 2025-08-11: +12% vs S&P +6% CNO 2023-05-19: +7% vs S&P +5% APO 2022-08-31: +19% vs S&P +0% ADI 2022-06-21: +1% vs S&P +4% AMD 2025-05-22: +49% vs S&P +10% AZO 2022-03-21: +3% vs S&P -17% AMT 2025-11-04: -3% vs S&P +3% CRM 2025-03-03: -9% vs S&P +1% CLVT 2025-08-05: -4% vs S&P +9% AYI 2026-04-10: +20% vs S&P +11% ASYS 2022-05-17: +13% vs S&P +5% AIR 2021-07-29: -6% vs S&P +3% BST 2022-02-04: -14% vs S&P -7% BCAT 2021-11-24: -12% vs S&P -8% OPBK 2022-11-08: +6% vs S&P +8% CWH 2022-05-19: +22% vs S&P +10% BUSE 2025-03-12: +8% vs S&P +8% ASPI 2024-07-10: -19% vs S&P +2% BRCC 2025-08-11: -15% vs S&P +6% CLVT 2021-06-15: -5% vs S&P +6% CRSR 2021-04-09: -7% vs S&P +5% CLX 2025-05-09: -6% vs S&P +12% ACNB 2021-07-01: -2% vs S&P +1% BAH 2024-11-25: -23% vs S&P +1% ARKR 2022-06-28: +2% vs S&P -4% AHCO 2021-03-18: -24% vs S&P +8% CME 2022-12-05: +6% vs S&P +2% CLNN 2022-03-30: -24% vs S&P -17% CCI 2020-12-14: +3% vs S&P +9% LEU 2023-03-17: +7% vs S&P +13% CMI 2025-05-16: +22% vs S&P +9% BHR 2022-05-18: +1% vs S&P +10% BRCC 2025-11-19: -43% vs S&P +3% MEGI 2025-01-06: +3% vs S&P -15% ARDX 2025-01-22: -5% vs S&P -13% CRK 2022-08-08: +24% vs S&P -8% BH 2026-06-05: +31% vs S&P +5% XMTR 2024-05-31: +32% vs S&P +6% CMTG 2022-08-18: -1% vs S&P -7% BHVN 2023-08-31: +76% vs S&P +1% DAL 2023-04-27: +40% vs S&P +11% AOSL 2026-03-10: +120% vs S&P +9% CRT 2026-06-26: +38% vs S&P +6% GBCI 2021-07-29: +3% vs S&P +3% COP 2025-11-10: +23% vs S&P +2% BKNG 2022-08-09: -6% vs S&P -7% ASTC 2022-09-07: -23% vs S&P -1% ASPU 2021-10-04: -59% vs S&P +11% CMG 2022-05-20: +32% vs S&P +10% AGO 2022-08-09: +12% vs S&P -7% JKHY 2023-05-30: +7% vs S&P +6% BSTZ 2025-03-14: +9% vs S&P +8% CTOS 2023-05-16: +3% vs S&P +10% BALL 2022-12-07: +5% vs S&P +2% AAACX 2020-07-28: -1% vs S&P +6% CORT 2020-09-01: +81% vs S&P +3% BV 2026-08-06: +10% vs S&P +0% AEYE 2025-11-24: -42% vs S&P +3% ADC 2026-06-08: +0% vs S&P +4% ADBE 2025-01-30: -16% vs S&P -8% ALIT 2021-12-10: -13% vs S&P -9% ADSK 2026-05-29: +17% vs S&P +2% BRC 2022-03-16: +2% vs S&P -14% DAL 2021-12-01: +12% vs S&P -4% AGEN 2024-02-15: -17% vs S&P +6% ALIT 2025-05-20: -31% vs S&P +9% ARDX 2024-11-14: +16% vs S&P +2% ALIT 2022-03-15: -20% vs S&P -12% AWK 2023-11-06: -3% vs S&P +14% ADC 2025-06-13: -0% vs S&P +10% CMTV 2024-08-05: +7% vs S&P +11% OSG 2020-07-13: +1% vs S&P +11% FBK 2023-06-09: -3% vs S&P +4% CCI 2022-02-24: +16% vs S&P -7% ARTV 2026-07-31: -58% vs S&P +3% CBNA 2025-03-03: +12% vs S&P +1% FBK 2025-02-14: -11% vs S&P -3% APTV 2025-12-16: -8% vs S&P -1% CBOE 2020-11-05: +15% vs S&P +9% BAX 2020-04-01: +10% vs S&P +26% ONEW 2023-02-23: -3% vs S&P +3% CSX 2022-05-16: +4% vs S&P +7% ACR 2023-01-04: +8% vs S&P +7% THG 2021-11-30: +15% vs S&P -4% AMG 2026-05-06: +25% vs S&P +5% AXR 2023-10-13: +31% vs S&P +11% BX 2022-03-01: -1% vs S&P -3% AMPY 2023-03-15: +1% vs S&P +13% AES 2021-09-16: -0% vs S&P +6% CFR 2020-02-10: -25% vs S&P -12% BWFG 2023-03-23: -0% vs S&P +11% BOTJ 2021-08-23: +14% vs S&P +5% CARG 2026-03-04: -15% vs S&P +11% BDX 2025-02-10: -27% vs S&P -6% LMND 2026-03-30: +0% vs S&P +16% CRSP 2025-02-28: -16% vs S&P -0% LMNR 2021-09-28: +4% vs S&P +10% BRCC 2023-12-12: +15% vs S&P +11% AGL 2026-03-03: +553% vs S&P +12% BMBL 2022-03-18: +2% vs S&P -18% BX 2022-05-25: -7% vs S&P +4% ACR 2022-09-06: +1% vs S&P +3% BWFG 2022-06-28: -5% vs S&P -4% ARDC 2022-01-27: -8% vs S&P -3% MED 2021-11-10: -11% vs S&P -2% CAG 2023-10-10: +6% vs S&P +10% CAG 2021-07-16: -2% vs S&P +3% CRL 2023-02-24: -11% vs S&P +5% MEGI 2024-03-20: +2% vs S&P +5% C 2020-09-04: +9% vs S&P +7% AOS 2022-02-22: -16% vs S&P -7% BCO 2022-06-14: +1% vs S&P +10% This buy: result due Feb 18, 2027
Median vs. S&P 500 +0.0%
Average vs. S&P 500 +5.4%
Best +552.8%
Worst -59.3%
History, not a prediction: what happened next in similar past cases, measured from the day the last filing became public. Not investment advice.
By InsiderPrint Research Desk · Updated Nov 20, 2026 · Sources: SEC EDGAR Form 4 filings , FINRA short-sale volume · How we calculate this
ELV insider buying and selling by quarter Open-market purchases (green, above the line) and sales (red, below), by trade date.
Q1 2026: $870K bought (1 trades) $870K Q1 2026: $918K sold (2 trades) Q1 2026 Q2 2026: $827K sold (3 trades) Q2 2026 Q3 2026: $1.4M bought (3 trades) $1.4M Q3 2026 Q4 2026: $384K bought (1 trades) $384K Q4 2026: $5.2M sold (14 trades) Q4 2026
Quarter Bought Purchases Sold Sales
Q4 2026 $384K 1 $5.2M 14 Q3 2026 $1.4M 3 — 0 Q2 2026 — 0 $827K 3 Q1 2026 $870K 1 $918K 2
P/E (trailing) 14.9 Sector median 25.0
Volume vs. 50-day 1.1× Last 5 sessions
Insiders' paper profit +$400K On all tracked purchases +15.3%
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 3 Elevance Health insiders reported open-market purchases totaling $2.6M, while 6 insiders reported sales totaling $7.0M. Among insiders with enough purchase history to measure, Steven H. Collis (Director) has the highest Insider Score at 54. 0 of 19 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ELV earnings: how the stock reacted Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
Does it matter? →
Release 15 days before Insiders, 30 days before Reaction (2 days) Next 30 days
Oct 21, 2026
+11.6%
None
+1.2% S&P -0.7%
pending
Jul 15, 2026
+10.0%
None
-12.6% S&P -0.1%
+7.4%
Apr 22, 2026
+8.4%
None
+5.5% S&P +0.6%
+14.0%
Jan 28, 2026
-13.9%
None
+7.5% S&P -0.2%
-7.8%
Oct 21, 2025
+1.0%
None
-2.5% S&P -0.5%
-6.8%
Jul 17, 2025
-12.9%
None
-19.6% S&P +0.5%
+11.7%
Apr 22, 2025
-5.2%
None
+5.0% S&P +4.2%
-12.8%
Apr 17, 2025
+0.5%
None
-6.5% S&P -2.2%
-1.6%
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
ELV short selling Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
20% 40% 60% 2026-08-26: 43% of volume sold short 2026-08-27: 51% of volume sold short 2026-08-28: 64% of volume sold short 2026-08-31: 63% of volume sold short 2026-09-01: 66% of volume sold short 2026-09-02: 57% of volume sold short 2026-09-03: 71% of volume sold short 2026-09-04: 76% of volume sold short 2026-09-08: 63% of volume sold short 2026-09-09: 73% of volume sold short 2026-09-10: 56% of volume sold short 2026-09-11: 65% of volume sold short 2026-09-14: 46% of volume sold short 2026-09-15: 66% of volume sold short 2026-09-16: 56% of volume sold short 2026-09-17: 41% of volume sold short 2026-09-18: 51% of volume sold short 2026-09-21: 63% of volume sold short 2026-09-22: 46% of volume sold short 2026-09-23: 37% of volume sold short 2026-09-24: 45% of volume sold short 2026-09-25: 45% of volume sold short 2026-09-28: 49% of volume sold short 2026-09-29: 52% of volume sold short 2026-09-30: 49% of volume sold short 2026-10-01: 55% of volume sold short 2026-10-02: 44% of volume sold short 2026-10-05: 76% of volume sold short 2026-10-06: 58% of volume sold short 2026-10-07: 58% of volume sold short 2026-10-08: 59% of volume sold short 2026-10-09: 39% of volume sold short 2026-10-12: 60% of volume sold short 2026-10-13: 66% of volume sold short 2026-10-14: 61% of volume sold short 2026-10-15: 36% of volume sold short 2026-10-16: 46% of volume sold short 2026-10-19: 53% of volume sold short 2026-10-20: 45% of volume sold short 2026-10-21: 46% of volume sold short 2026-10-22: 62% of volume sold short 2026-10-23: 51% of volume sold short 2026-10-26: 55% of volume sold short 2026-10-27: 30% of volume sold short 2026-10-28: 46% of volume sold short 2026-10-29: 44% of volume sold short 2026-10-30: 40% of volume sold short 2026-11-02: 20% of volume sold short 2026-11-03: 32% of volume sold short 2026-11-04: 47% of volume sold short 2026-11-05: 40% of volume sold short 2026-11-06: 68% of volume sold short 2026-11-09: 40% of volume sold short 2026-11-10: 53% of volume sold short 2026-11-11: 47% of volume sold short 2026-11-12: 49% of volume sold short 2026-11-13: 64% of volume sold short 2026-11-16: 58% of volume sold short 2026-11-17: 59% of volume sold short 2026-11-18: 40% of volume sold short Aug 26 Sep 10 Sep 24 Oct 8 Oct 22 Nov 5
Latest (Nov 18): 40% 20-day average: 45% Prior 2 months: 53%
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded ELV From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
All Congress trades →
Member Trade Traded Reported Since trade
Alan Armstrong Senate
Bought $1,001 - $15,000
Mar 27, 2026 Jul 21, 2026
+37.7%
Markwayne Mullin Senate
Bought $15,001 - $50,000
Dec 29, 2025 Jan 16, 2026
+13.9%
What happened after ELV insiders bought Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.
Across all stocks →
Filed Insider Bought 7 days 30 days 90 days
Nov 20, 2026 Ramiro G. Peru Director $384K
pending pending pending Jul 17, 2026 Ramiro G. Peru Director $366K
+1.2% +1.8% vs S&P +4.6% +0.6% vs S&P +15.3% +11.2% vs S&P Jul 17, 2026 Gail Boudreaux CEO, President $1.0M
+1.2% +1.8% vs S&P +4.6% +0.6% vs S&P +15.3% +11.2% vs S&P Mar 6, 2026 Steven H. Collis Director $870K
+1.3% +2.8% vs S&P +5.1% +6.9% vs S&P +42.2% +29.3% vs S&P
Insiders at Elevance Health
Insider Bought Sold Last filing Past buys beat S&P Score
Mark Kaye CFO
—
$4.7M
Oct 23, 2026
—
—
Gail Boudreaux CEO, President
$1.0M
—
Jul 17, 2026
—
—
Steven H. Collis Director
$870K
—
May 15, 2026
0 of 1
54
Ramiro G. Peru Director
$750K
—
Nov 20, 2026
—
—
Charles Morgan Kendrick Jr. President
—
$911K
Mar 9, 2026
—
—
Ronald W. Penczek Cao & Controller
—
$766K
Jun 15, 2026
—
—
Ratnakar Lavu Evp & Chief Digital Info Ofr
—
$572K
Nov 6, 2026
—
—
Robert L. Dixon Jr. Director
—
$61K
Jun 12, 2026
—
—
Amy W. Schulman Director
—
$7K
May 15, 2026
—
—
Erin M. Wessling General Counsel
—
—
Sep 4, 2026
—
—
Ryan R. Craig Evp & Chief Hr Officer
—
—
Sep 4, 2026
—
—
Lewis Hay III Director
—
—
May 15, 2026
—
—
Ryan M. Schneider Director
—
—
May 15, 2026
—
—
Susan D. Devore Director
—
—
May 15, 2026
—
—
Deanna D. Strable-Soethout Director
—
—
May 15, 2026
—
—
Antonio F. Neri Director
—
—
May 15, 2026
—
—
Bahija Jallal Director
—
—
May 15, 2026
—
—
Felicia F. Norwood Evp &Chief Health Benefits Ofr
—
—
Mar 4, 2026
—
—
Peter D. Haytaian Evp & Pres Carelon & Carelonrx
—
—
Mar 4, 2026
—
—
Board links: companies that share insiders with ELV Directors and executives who filed Form 4s for ELV and another company in the last 12 months.
See the map →
ALNY Alnylam Pharmaceuticals
Amy W. Schulman Director here · Director at ALNY · latest filing Nov 12, 2026 BLCO Bausch & Lomb
Steven H. Collis Director here · Director at BLCO · latest filing May 15, 2026 HPE Hewlett Packard Enterprise
Antonio F. Neri Director here · CEO, President at HPE · latest filing Oct 7, 2026 IMCR Immunocore Holdings
Bahija Jallal Director here · CEO at IMCR · latest filing May 15, 2026 LHX L3Harris
Lewis Hay III Director here · Director at LHX · latest filing May 15, 2026 PFG Principal Financial Group
Deanna D. Strable-Soethout Director here · CEO, President at PFG · latest filing Sep 29, 2026 SM SM Energy
Ramiro G. Peru Director here · Director at SM · latest filing Nov 20, 2026 SOLV Solventum
Susan D. Devore Director here · Director at SOLV · latest filing May 15, 2026 TGT Target
Gail Boudreaux CEO, President here · Director at TGT · latest filing Jul 17, 2026
Insider activity at other Health Care companies Same sector, ranked by insider buying in the last 90 days.
KOD Kodiak Sciences Inc. $181M bought BBTX Bambusa Therapeutics, Inc. $52.6M bought WWB WINDWARD BIO GROUP AG $49.8M bought ADRX ADARx Pharmaceuticals, Inc. $43.4M bought PEPG PepGen Inc. $43.1M bought LYCA Lycia Therapeutics, Inc. $38.5M bought
ELV stock: common questions
Are Elevance Health insiders buying ELV stock? In the past 12 months, 3 insiders reported open-market purchases of ELV worth $2.6M. The latest was Director Ramiro G Peru bought $384K of ELV at $383.86.
Are Elevance Health insiders selling ELV stock? 6 insiders reported sales worth $7.0M over the same period.
Where does this data come from? Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ELV's P/E ratio? ELV trades at about 14.9 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is ELV's 52-week range? Over the past year ELV has traded between $276.69 and $446.28. It last closed at $391.13 on Nov 19, 2026.